Osimertinib Treatment Was Unsuccessful for Lung Adenocarcinoma with G719S, S768I, and T790M Mutations

Epidermal growth factor receptor (EGFR) T790M mutations are the most frequent mechanism of resistance to first- and second-generation tyrosine kinase inhibitors, and osimertinib is an effective treatment for patients with both EGFR-activating mutations and T790M resistance mutations. We describe the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Intern Med
Autors principals: Nasu, Shingo, Shiroyama, Takayuki, Morita, Satomu, Takata, So, Takada, Hiromune, Masuhiro, Kentaro, Tanaka, Ayako, Morishita, Naoko, Suzuki, Hidekazu, Okamoto, Norio, Hirashima, Tomonori
Format: Artigo
Idioma:Inglês
Publicat: The Japanese Society of Internal Medicine 2018
Matèries:
Case Report
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6355418/
https://ncbi.nlm.nih.gov/pubmed/30146570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2169/internalmedicine.0923-18
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars